Blood diagnostic company Haemokinesis Limited is ASX-bound, with its $17 million share issue, at 20 cents a share, closing this Wednesday, with Haemokinesis expected to commence trading on the exchange on Friday, 8 April. When it hits the screens Haemokinesis will have a market capitalisation of $77 million. Haemokinesis – which means “moving blood with…
What many people thought was a term from an economic history book, “energy crisis” has returned to the headlines, as rising global energy demand encounters restrictions on supply – and geo-political spot fires aplenty, with the Russia/Ukraine border a particular focus. In the old days, when people were familiar with the term “energy crisis,” there…
Everyone involved in the share market understands – or should understand – that pricing an initial public offering (IPO) is not an easy task. The underwriters or lead managers are trying to ascertain what the market will pay: they will test the marketability of the company by discreetly querying major investors on how much they…
Australia’s super funds have posted a remarkable tenth consecutive calendar-year gain, with the median growth fund (having 61 per cent-80 per cent in growth assets) returning an impressive 13.4 per cent, according to the Zenith-owned research, data and analytics firm Chant West. The category is used as a proxy for the performance of super funds…
Is this greenwashing, or simply a business trying to ensure that its operations are conducted as responsibly as possible? Dalrymple Bay Infrastructure Limited (ASX: DBI), which listed in December 2020, is a unique business; it operates a major infrastructure asset – the Dalrymple Bay Coal Terminal on the central Queensland coast – that ships coal…
Specialist small- and micro-cap Australian equities investment manager NAOS Asset Management has taken its philosophy into the private markets, with the launch of its Private Opportunities Fund, for which it is seeking to raise at least $35 million. The fund will invest in up to 20 private companies that NAOS identifies as being profitable, having…
The resources exploration-project development end of the Australian Securities Exchange (ASX) is an exciting place to spend time; one really gets a sense of how the share market kicked-off in Australia in the 1850s, when no boomtime goldfield town was complete without its own stock exchange. It is, potentially, the home of the multi-bagger –…
An essential part of developing a drug is the requirement for tests on human volunteers, usually starting in Phase 1. But for Noxopharm’s Veyonda drug, the first human volunteer was the company’s CEO and managing director, Dr. Graham Kelly. It was 2014, and some of the top cancer specialists in Australia had told Kelly that…
Sydney-based drug developer Pharmaxis (ASX:PXS) is moving through a pivot that the market is taking its time to understand, as it takes its lead drug candidate PXSâ€5505 firstly through a Phase 1/2a trial for the treatment of the rare bone marrow cancer myelofibrosis, and secondly, into pre-clinical efficacy testing for glioblastoma (GBM), the most common form…
If you want to find gold, one of the best theories to go on is to look where it’s been found before – and that’s what Theta Gold Mines Limited (ASX: TGM) has done. Theta’s core project is located in the Eastern Transvaal Gold Fields of South Africa, where that country’s gold mining industry began…
